MedTrace Logo

Clinical Study of Nab-paclitaxel Combined With Toripalimab in Local Advanced or Metastatic G/GEJ Carcinoma

NCT04443036 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2020-06-23

No results posted yet for this study

Summary

This study is to evaluate the efficacy and safety of Albumin-bound paclitaxel combined with Toripalimab as first-line/second-line treatment of local advanced or metastatic gastric or gastroesophageal junction carcinoma.

Conditions

  • Gastric Carcinoma

Interventions

DRUG

Albumin-Bound Paclitaxel

* 125mg/m2 IV d1、8，Q3W * until disease progression, lost follow-up visit, death , unacceptable toxicity

DRUG

Toripalimab

* 240 mg，IV d1，Q3W * until disease progression, lost follow-up visit, death , unacceptable toxicity, Maximum treatment duration is 24 months

Sponsors & Collaborators

  • China Medical University, China

    lead OTHER

Principal Investigators

  • Yunpeng Liu, PhD. · First Hospital of China Medical University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-11
Primary Completion
2022-12-30
Completion
2023-12-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04443036 on ClinicalTrials.gov